Recently Hsiue et al. [209] generated bi-specific antibodies that targeted mutant p53 R175H and CD3, which have been shown effective in targeting cancer cells, including the ovarian cancer cell line TYK-nu in vitro and in vivo in mice. The gene discussed is TP53; the disease is ovarian cancer.